ChinaAMC says it sees investment opportunities in value stocks and large blue-chip names. Its CEO Yimei Li says international investors are showing strong interest in Chinese assets, adding that solid economic activity could act as a catalyst for gains. She speaks with David Ingles on “Bloomberg: The China Show.” (Source: Bloomberg)
ChinaAMC says it sees investment opportunities in value stocks and large blue-chip names. Its CEO Yimei Li says international investors are showing strong interest in Chinese assets, adding that solid economic activity could act as a catalyst for gains. She speaks with David Ingles on “Bloomberg: The China Show.” (Source: Bloomberg)
Alphabet is experiencing strong demand for its AI cloud services. Alphabet (GOOG 1.78%) (GOOGL 1.77%) stock made a monster comeback in 2025, rocketing 107% after the sharp sell-off in April, and the real growth story is happening in Google Cloud. Enterprise demand for artificial intelligence (AI) tools is off the charts, and Alphabet is not only reporting strong revenue growth, but also turning th...
Alphabet is experiencing strong demand for its AI cloud services. Alphabet (GOOG 1.78%) (GOOGL 1.77%) stock made a monster comeback in 2025, rocketing 107% after the sharp sell-off in April, and the real growth story is happening in Google Cloud. Enterprise demand for artificial intelligence (AI) tools is off the charts, and Alphabet is not only reporting strong revenue growth, but also turning this demand into soaring profits. Google Cloud's operating income jumped 154% year over year in the fourth quarter, contributing to the company's double-digit earnings growth over the past year. Here's what investors should know before deciding whether to buy Google stock now. Google Cloud is turning into a real growth catalyst for the company, particularly on the bottom line. Cloud revenue increased by 48% year over year -- a noticeable acceleration over the previous quarter's 34% increase -- with operating income reaching $5.3 billion in the fourth quarter. However, Google Cloud still contributes just 15% of Alphabet's total operating profit. This is still primarily a digital advertising business, with that making up 72% of the company's fourth-quarter revenue. Expand NASDAQ : GOOGL Alphabet Today's Change ( -1.77 %) $ -5.74 Current Price $ 318.58 Key Data Points Market Cap $3.9T Day's Range $ 314.61 - $ 321.67 52wk Range $ 140.53 - $ 349.00 Volume 39M Avg Vol 37M Gross Margin 59.68 % Dividend Yield 0.26 % Investors should also be prepared for a dip in the share price. Wall Street doesn't like anything that causes uncertainty to near-term earnings visibility. Alphabet is planning to double capital spending in 2026, and this could pressure the share price in the near term. Still, Alphabet is directing more investment into its AI infrastructure. AI is the future, and the companies that own hard assets -- data centers and chips -- will ultimately capture much of the profit from this technology, as Alphabet is already demonstrating. Google stock is not as cheap as it was a year...
Key Points Google Cloud revenue increased 48% year over year in the most recent quarter, while operating income reached $5.3 billion. The company will have to spend aggressively to keep up with demand. Alphabet stock is trading at 29 times 2026 earnings estimates. 10 stocks we like better than Alphabet › Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) stock made a monster comeback in 2025, rocketing 107% ...
Key Points Google Cloud revenue increased 48% year over year in the most recent quarter, while operating income reached $5.3 billion. The company will have to spend aggressively to keep up with demand. Alphabet stock is trading at 29 times 2026 earnings estimates. 10 stocks we like better than Alphabet › Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) stock made a monster comeback in 2025, rocketing 107% after the sharp sell-off in April, and the real growth story is happening in Google Cloud. Enterprise demand for artificial intelligence (AI) tools is off the charts, and Alphabet is not only reporting strong revenue growth, but also turning this demand into soaring profits. Google Cloud's operating income jumped 154% year over year in the fourth quarter, contributing to the company's double-digit earnings growth over the past year. Here's what investors should know before deciding whether to buy Google stock now. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Google Cloud is turning into a real growth catalyst for the company, particularly on the bottom line. Cloud revenue increased by 48% year over year -- a noticeable acceleration over the previous quarter's 34% increase -- with operating income reaching $5.3 billion in the fourth quarter. However, Google Cloud still contributes just 15% of Alphabet's total operating profit. This is still primarily a digital advertising business, with that making up 72% of the company's fourth-quarter revenue. Investors should also be prepared for a dip in the share price. Wall Street doesn't like anything that causes uncertainty to near-term earnings visibility. Alphabet is planning to double capital spending in 2026, and this could pressure the share price in the near term. Still, Alphabet is directing more investment into its AI infrastructure. AI is the future, and the companies that own hard assets -- data cente...
WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing. In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yua...
WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing. In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yuan (US$710 million), while revenue is set to climb 16.7 per cent to 21.79 billion yuan. Shares rose 3.2 per cent to HK$41.32 at the noon trading break, extending their year-to-date gain to 31.4 per cent. Advertisement WuXi Biologics credited the performance to its “follow and win the molecule” strategy, which aims to secure work across the full life cycle of client drugs – from early research to late-stage development and commercial production – supported by its technology platforms and execution track record. The model allows the group to partner with both emerging biotech firms and multinational drug makers, tracking client molecules through development while capturing late-stage and commercial manufacturing projects. Advertisement The company, headquartered in Wuxi, in Jiangsu province, eastern China, added 209 new integrated projects in 2025. Among them were 23 under its “win the molecule” strategy, including six in Phase III trials and commercial production, bringing the total to 945, CEO Chris Chen said at the JPMorgan Healthcare Conference in San Francisco last month.
Suzano S.A. press release ( SUZ ): Q4 Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. Operational efficiency also helped Suzano deliver operating cash generation of R$13.9 billion in 2025, despite less supportive global market price conditions. Adjusted EBITDA totalled R$21.7 billi...
Suzano S.A. press release ( SUZ ): Q4 Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. Operational efficiency also helped Suzano deliver operating cash generation of R$13.9 billion in 2025, despite less supportive global market price conditions. Adjusted EBITDA totalled R$21.7 billion, and net income closed the year at R$13.4 billion. Suzano’s net leverage in U.S. dollars ended December 2025 at 3.2 times, down from 3.3 times in the third quarter. More on Suzano S.A. Suzano: A Few Good Reasons To Believe The Worst Is Likely Behind Suzano S.A. (SUZ) Analyst/Investor Day Transcript Suzano S.A. (SUZ) Analyst/Investor Day - Slideshow Kimberly-Clark updates on its joint venture with Suzano Seeking Alpha’s Quant Rating on Suzano S.A.
Zhengzhou University First Affiliated Hospital In an operating room at one of China’s largest medical centers, a surgeon unpacked a microvascular anastomosis device costing 16,800 yuan ($2,430) and tossed it directly into the trash. The patient, unconscious on the table, would later receive a bill for the expensive consumable. A recent court ruling has exposed this scene as part of a four-year fra...
Zhengzhou University First Affiliated Hospital In an operating room at one of China’s largest medical centers, a surgeon unpacked a microvascular anastomosis device costing 16,800 yuan ($2,430) and tossed it directly into the trash. The patient, unconscious on the table, would later receive a bill for the expensive consumable. A recent court ruling has exposed this scene as part of a four-year fraud scheme at Zhengzhou University First Affiliated Hospital. According to the verdict, Wang Fujian, a former deputy chief physician in the emergency surgery department, used 128 unsuitable devices during surgeries between February 2016 and July 2020. He defrauded 94 victims — including children as young as 1 — of more than 2.05 million yuan, with the funds flowing into the hospital’s accounts.
Slate Grocery REIT press release ( SRRTF ): Q4 FFO per WA units of $0.25. Revenue of $54.61M (+2.9% Y/Y) beats by $1.54M . More on Slate Grocery REIT Slate Grocery REIT: My Top 1 REIT For Monthly Passive Income Seeking Alpha’s Quant Rating on Slate Grocery REIT Historical earnings data for Slate Grocery REIT Dividend scorecard for Slate Grocery REIT Financial information for Slate Grocery REIT
Slate Grocery REIT press release ( SRRTF ): Q4 FFO per WA units of $0.25. Revenue of $54.61M (+2.9% Y/Y) beats by $1.54M . More on Slate Grocery REIT Slate Grocery REIT: My Top 1 REIT For Monthly Passive Income Seeking Alpha’s Quant Rating on Slate Grocery REIT Historical earnings data for Slate Grocery REIT Dividend scorecard for Slate Grocery REIT Financial information for Slate Grocery REIT
海關水路兩度截獲私煙 市值約6800萬元 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】海關打擊私煙，經水路截獲共1,500多萬支懷疑未完稅煙，市值約6,800萬元，拘捕8人。 海關上月底及本月初兩次行動，檢獲大...
海關水路兩度截獲私煙 市值約6800萬元 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】海關打擊私煙，經水路截獲共1,500多萬支懷疑未完稅煙，市值約6,800萬元，拘捕8人。 海關上月底及本月初兩次行動，檢獲大批懷疑未完稅煙，應課稅值約5,000萬元。首次行動在南丫島對開水域，截查一艘遠洋貨船，在船上四個空載貨櫃暗格，發現762萬支懷疑私煙。另一次行動就在葵涌海關驗貨場，查驗由台灣抵港貨櫃，檢獲約760萬支懷疑私煙。海關相信農曆年臨近，不法集團走私供應本地及海外市場。
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Inno...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals show Eli Lilly leaning further into complex biologic and genetic medicines, areas that are drawing significant R&D attention across large pharma. Orna's circular RNA platform and in vivo cell therapies sit within a broader industry push to find new treatment approaches for autoimmune conditions, while the Innovent tie up adds more drug candidates across cancer and immune disorders. Together, they expand the kinds of therapies represented in Lilly's pipeline. Looking ahead, the key questions will center on how quickly these programs progress through clinical development, and how risks and costs are managed across such a broad research agenda. You may want to track future disclosures around trial starts, regulatory interactions, and any early clinical data, as these will shape how meaningful these moves become for Eli Lilly's long term profile. Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly. NYSE:LLY 1-Year Stock Price Chart Why Eli Lilly could be great value Quick Assessment ⚖️ Price vs Analyst Target : At US$1,025, the share price is about 15% below the US$1,201.63 analyst target, with a wide range from US$830 to US$1,500. ✅ Simply Wall St Valuation : The stock is flagged as trading 26.7% below estimated fa...